DoW Bone Marrow Failure, Idea Development Award

The Bone Marrow Failure Research Program Idea Development Award is administered by the Defense Health Agency through the Congressionally Directed Medical Research Programs. This federal funding opportunity is designed to advance research focused on bone marrow failure diseases, which include both inherited and acquired conditions affecting the body’s ability to produce blood cells. The program reflects a broader congressional initiative launched in 2008 to support high-impact biomedical research with the goal of improving outcomes for service members, veterans, and the general public. The administering office seeks to fund scientifically rigorous and innovative studies that align with its long-term vision of understanding and ultimately curing bone marrow failure diseases. The primary purpose of the Idea Development Award is to support novel, high-risk, high-reward research that can generate meaningful data and open new avenues of scientific investigation. Projects funded under this mechanism are expected to address key focus areas such as identifying effective treatments or cures and improving understanding of disease causes and progression. The program explicitly encourages innovative approaches that challenge existing paradigms or introduce new methodologies. Importantly, preliminary data is not required, allowing investigators to propose exploratory concepts that are grounded in strong scientific rationale but may not yet be fully validated. Funding for this opportunity is structured to support approximately five awards with a maximum total cost of 800,000 dollars per project over a period of up to three years. The total program funding is expected to be approximately 4 million dollars. Funds may be used for research-related expenses including personnel, supplies, and limited travel to scientific meetings, particularly for disseminating results. However, clinical trials themselves are not allowed under this mechanism, although correlative studies associated with clinical trials may be supported. There is no requirement for cost sharing or matching funds, which lowers the barrier to entry for eligible applicants. Eligibility for the program is broad and inclusive. Both domestic and international organizations may apply, including public and private institutions, nonprofit organizations, for-profit entities, and government agencies. Principal Investigators must be independent investigators affiliated with an eligible organization and may apply as either Early-Career Investigators or Established Investigators, depending on their years of experience since their first independent appointment. The program allows significant flexibility in investigator background and encourages multidisciplinary collaboration, including partnerships with military or federal agencies. The application process follows a two-step submission model. Applicants must first submit a pre-application through the Electronic Biomedical Research Application Portal. Only those invited based on the pre-application review may submit a full application, which is then submitted through Grants.gov or eBRAP depending on the organization type. The pre-application includes a narrative describing the research idea, innovation, impact, and personnel, while the full application requires detailed components such as a project narrative, technical and lay abstracts, statement of work, and supporting documentation including letters of support and data sharing plans. Applications are evaluated through a multi-tiered review process. Pre-applications are screened for alignment with program objectives, innovation, and potential impact. Full applications undergo peer review to assess scientific merit, feasibility, and methodological rigor, followed by programmatic review to evaluate relevance to program priorities and overall portfolio balance. Key evaluation criteria include innovation, impact, research strategy, statistical rigor, and the qualifications of the research team. The timeline for this funding opportunity includes a pre-application deadline in early August, followed by invitations for full applications in mid-September and a final application deadline in early November. Peer review occurs in January, with programmatic review in March, and funding decisions expected thereafter. Awards are anticipated to be made by late September of the following year. The program does not explicitly state recurrence, but given its fiscal year designation, it is likely part of an annual funding cycle.

Focus on innovation and high-impact ideas; clearly align with BMFRP focus areas; demonstrate feasibility without relying on preliminary data; ensure strong rationale and well-defined hypothesis